Related Experiment Video

Updated: Feb 11, 2026

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.5K

Glioma and Neurokinin-1 Receptor Antagonists: A New Therapeutic Approach

Miguel Muñoz1, Rafael Coveñas2

  • 1Virgen del Rocío University Hospital, Research Laboratory on Neuropeptides (IBIS), Seville, Spain.

Anti-Cancer Agents in Medicinal Chemistry
|April 26, 2018
PubMed
Abstract

Insights

New research highlights the critical role of the neurokinin (NK)-1 receptor/Substance P (SP) system in glioblastoma development. NK-1 receptor antagonists show promise as novel anti-glioma drugs, offering potential new treatments.

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Glioblastoma is a lethal primary brain tumor with poor prognosis despite aggressive therapies.
  • The blood-brain barrier limits conventional chemotherapy efficacy, leading to high recurrence rates.
  • The neurokinin (NK)-1 receptor/Substance P (SP) system is implicated in glioma progression, with glioma cells overexpressing NK-1 receptors.

Purpose of the Study:

  • To review the involvement of the NK-1 receptor/SP system in glioma development.
  • To explore the potential of NK-1 receptor antagonists as therapeutic agents against glioma.

Main Methods:

  • Literature review focusing on the molecular mechanisms of NK-1 receptor signaling in glioma.
  • Analysis of studies investigating the effects of NK-1 receptor antagonists on glioma cell behavior.

Main Results:

  • The NK-1 receptor/SP system promotes glioma cell proliferation, migration, angiogenesis, and inflammation.
  • SP facilitates glycogen breakdown for glycolysis in glioma cells.
  • NK-1 receptor antagonists inhibit glioma cell proliferation, glycogenolysis, and angiogenesis, while promoting apoptosis.

Conclusions:

  • The NK-1 receptor plays a significant role in glioma pathogenesis.
  • NK-1 receptor antagonists represent a promising therapeutic strategy for combating glioma.
Keywords:
Substance Pangiogenesisantitumorapoptosisaprepitantglioblastomametastasissignalling pathway.

More Related Videos

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

13.2K
Prediction of HIV-1 Coreceptor Usage Tropism by Sequence Analysis using a Genotypic Approach07:06

Prediction of HIV-1 Coreceptor Usage Tropism by Sequence Analysis using a Genotypic Approach

Published on: December 1, 2011

13.7K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
641
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.5K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
5.1K
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.8K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.4K